Clifford Chance advises the Underwriters on Agomab Therapeutics’ IPO

Clifford Chance has acted as Belgian counsel to the underwriters J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen on the successful initial public offering of Agomab Therapeutics NV on the Nasdaq Global Market.

Agomab Therapeutics, based in Antwerp, Belgium, is a clinical-stage biopharmaceutical company developing innovative therapies for fibrotic diseases by targeting growth factor signalling pathways. The IPO, structured as a primary offering of American Depositary Shares (ADSs), raised $200 million.

The Clifford Chance team was led by Niek De Pauw (Partner) and Gillis Waelkens (Counsel) and further comprised Céline Lievens (Associate), Wim Aerts (Senior Counsel) and Thomas Linard de Guertechin (Senior Associate).